GSK’s Myeloma Drug Gets AdComm Backing, But Limitations Remain Clear
Likely To Be First BCMA Approval
Executive Summary
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.